Egli Nicole, Zajonz Alexandra, Burger Matthew T, Schweighoffer Tamas
Autoimmune, Transplantation, and Inflammatory Diseases Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
PLoS One. 2015 Nov 10;10(11):e0142741. doi: 10.1371/journal.pone.0142741. eCollection 2015.
Toll-like receptors (TLRs) are important sensors of the innate immune system that recognize conserved structural motifs and activate cells via a downstream signaling cascade. The CD180/MD1 molecular complex is an unusual member of the TLR family, since it lacks the components that are normally required for signal transduction by other TLRs. Therefore the CD180/MD 1 complex has been considered of being incapable of independently initiating cellular signals. Using chemogenetic approaches we identified specifically the membrane bound long form of PIM-1 kinase, PIM-1L as the mediator of CD180-dependent signaling. A dominant negative isoform of PIM-1L, but not of other PIM kinases, inhibited signaling elicited by cross-linking of CD180, and this effect was phenocopied by PIM inhibitors. PIM-1L was directed to the cell membrane by its N-terminal extension, where it colocalized and physically associated with CD180. Triggering CD180 also induced increased phosphorylation of the anti-apoptotic protein BAD in a PIM kinase-dependent fashion. Also in primary human B cells, which are the main cells expressing CD180 in man, cross-linking of CD180 by monoclonal antibodies stimulated cell survival and proliferation that was abrogated by specific inhibitors. By associating with PIM-1L, CD180 can thus obtain autonomous signaling capabilities, and this complex is then channeling inflammatory signals into B cell survival programs. Pharmacological inhibition of PIM-1 should therefore provide novel therapeutic options in diseases that respond to innate immune stimulation with subsequently increased B cell activity, such as lupus erythematosus or myasthenia gravis.
Toll样受体(TLRs)是先天性免疫系统的重要传感器,可识别保守的结构基序并通过下游信号级联反应激活细胞。CD180/MD1分子复合物是TLR家族的一个特殊成员,因为它缺乏其他TLR信号转导通常所需的成分。因此,CD180/MD1复合物被认为无法独立启动细胞信号。我们使用化学遗传学方法特异性地鉴定出膜结合的PIM-1激酶长形式(PIM-1L)是CD180依赖性信号传导的介质。PIM-1L的显性负性异构体而非其他PIM激酶可抑制CD180交联引发的信号传导,PIM抑制剂也可模拟这种效应。PIM-1L通过其N端延伸定位于细胞膜,在那里它与CD180共定位并发生物理相互作用。触发CD180还以PIM激酶依赖性方式诱导抗凋亡蛋白BAD的磷酸化增加。同样在人类主要表达CD180的原代B细胞中,单克隆抗体交联CD180可刺激细胞存活和增殖,而特异性抑制剂可消除这种作用。通过与PIM-1L结合,CD180因此可以获得自主信号传导能力,然后这种复合物将炎症信号导入B细胞存活程序。因此,PIM-1的药理学抑制应该为那些对先天性免疫刺激有反应且随后B细胞活性增加的疾病提供新的治疗选择,如红斑狼疮或重症肌无力。